Your browser doesn't support javascript.
loading
Probing the CRL4DCAF12 interactions with MAGEA3 and CCT5 di-Glu C-terminal degrons.
Righetto, Germanna Lima; Yin, Yanting; Duda, David M; Vu, Victoria; Szewczyk, Magdalena M; Zeng, Hong; Li, Yanjun; Loppnau, Peter; Mei, Tony; Li, Yen-Yen; Seitova, Alma; Patrick, Aaron N; Brazeau, Jean-Francois; Chaudhry, Charu; Barsyte-Lovejoy, Dalia; Santhakumar, Vijayaratnam; Halabelian, Levon.
Afiliação
  • Righetto GL; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Yin Y; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
  • Duda DM; Structural and Protein Sciences, Therapeutics Discovery, Janssen Research and Development, Spring House, PA 19044, USA.
  • Vu V; Structural and Protein Sciences, Therapeutics Discovery, Janssen Research and Development, Spring House, PA 19044, USA.
  • Szewczyk MM; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Zeng H; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Li Y; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Loppnau P; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Mei T; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Li YY; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Seitova A; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Patrick AN; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Brazeau JF; Discovery Technology and Molecular Pharmacology, Therapeutics Discovery, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, USA.
  • Chaudhry C; Discovery Chemistry, Therapeutics Discovery, Janssen Research and Development, LLC, 3210 Merryfield Row, La Jolla, CA 92121, USA.
  • Barsyte-Lovejoy D; Discovery Technology and Molecular Pharmacology, Therapeutics Discovery, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, USA.
  • Santhakumar V; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Halabelian L; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
PNAS Nexus ; 3(4): pgae153, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38665159
ABSTRACT
Damaged DNA-binding protein-1 (DDB1)- and CUL4-associated factor 12 (DCAF12) serves as the substrate recognition component within the Cullin4-RING E3 ligase (CRL4) complex, capable of identifying C-terminal double-glutamic acid degrons to promote the degradation of specific substrates through the ubiquitin proteasome system. Melanoma-associated antigen 3 (MAGEA3) and T-complex protein 1 subunit epsilon (CCT5) proteins have been identified as cellular targets of DCAF12. To further characterize the interactions between DCAF12 and both MAGEA3 and CCT5, we developed a suite of biophysical and proximity-based cellular NanoBRET assays showing that the C-terminal degron peptides of both MAGEA3 and CCT5 form nanomolar affinity interactions with DCAF12 in vitro and in cells. Furthermore, we report here the 3.17 Šcryo-EM structure of DDB1-DCAF12-MAGEA3 complex revealing the key DCAF12 residues responsible for C-terminal degron recognition and binding. Our study provides new insights and tools to enable the discovery of small molecule handles targeting the WD40-repeat domain of DCAF12 for future proteolysis targeting chimera design and development.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: PNAS Nexus Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: PNAS Nexus Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá